Lpath, Inc. LPTN, the industry leader in bioactive lipid-targeted therapeutics,
received official notification from the European Patent Office (EPO)
and the U.S. Patent and Trademark Office (USPTO) that the company has
been issued three key patents.
The patents cover methods of detecting sphingolipid levels, as well
as covering monoclonal antibodies, including ASONEP(TM) and
iSONEP(TM), that bind to and neutralize sphingosine-1-phosphate
(S1P). S1P is a bioactive lipid that has been validated as a target
in multiple disease states.
The newly issued U.S. patent, No. 8,361,465, claims ASONEP and
fragments of ASONEP for the treatment of cancer in combination with
chemotherapeutic agents and optionally surgery or radiation therapy.
European patent No. EP 1 812 797 claims anti-S1P antibodies for use
in treating a wide range of hyperproliferative disorders, including
cancer, tumor angiogenesis, age-related macular degeneration (AMD),
cardiac failure, inflammation, and scarring. Claims are also granted
in Europe for anti-S1P antibodies in combination with other
treatments.
A third patent, EP 2 027 142, was also granted in Europe. It has
claims to reagents and methods useful in diagnostic tests for
detecting and measuring certain sphingolipid levels in clinical
tissue or bodily fluid samples. Many scientific publications have
suggested that S1P is a tumorigenic and angiogenic bioactive lipid
that cancer cells use to escape therapy. In collaboration with Dr. Rupal Bhatt of Beth Israel Deaconess Medical Center, Lpath has
demonstrated that levels of S1P are upregulated in blood of patients
with renal cell carcinoma (RCC). Moreover, Dr. Bhatt has demonstrated
efficacy of Lpath's anti-S1P antibodies in treating mice with human
RCC tumors.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: News
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in